Pfizer’s Xeljanz Approved by US FDA

Pfizer are celebrating today after US regulators approved their rheumatoid arthritis drug, Xeljanz, yesterday.  The treatment is the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis. The US Food and Drug Administration (FDA) have given the green light to Xeljanz (tofacitinib) 5mg twice-daily for the medication of adults with moderately to severely

Continue Reading

Scottish Medicines Consortium Approves Pfizer’s Xiapex

The Scottish Medicines Consortium (SMC) has authorised the use of Pfizer’s Xiapex (collagenase clostridium histolyticum) on the NHS for patients with Dupuytren’s contracture, reversing their earlier decision to reject the drug. Xiapex is the first medication available for the condition, which previously was only treatable with surgery, meaning that the SMC’s endorsement good news for

Continue Reading

FDA Approves Teva’s Generic Version of Lipitor

Generics major Teva Pharmaceutical Industries is set to enter the lucrative market created in the USA by the patent expiry on Pfizer’s Lipitor but not until Ranbaxy Laboratories’ 180-day exclusivity period runs out. The Israeli drugmaker noted that the US FDA (Food and Drug Administration) have granted tentative approval for their generic version of Lipitor,

Continue Reading

Pfizer gets EU approval for neurodegenerative disease drug

The European Commission (EC) has approved a new Pfizer drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare and fatal neurodegenerative disease affecting around 8,000 people worldwide. Vyndaqel (tafamidis; formerly Fx-1006A) becomes the first treatment approved anywhere in the world to treat the disease. The condition is characterised by deposits of amyloid

Continue Reading

deCode Announces Lupus Gene Agreement with Pfizer

deCODE genetics, headquartered in Reykjavik, Iceland, yesterday announced that they had entered into a research partnership with Pfizer.  The collaboration will seek to discover “sequence variants associated with specific clinical phenotypes related to systemic lupus erythematosis by utilizing the Reykjavik-based firm’s expertise in gene discovery”. Over the next 18 months, deCODE and Pfizer will work

Continue Reading